Trillium Therapeutics Inc. announced the appointment of Michael Kamarck, Ph.D., to its Board of Directors, effective immediately. Dr. Kamarck has significant expertise in biologics manufacturing and a breadth of management and technical experience, having served in senior leadership positions at a number of leading pharmaceutical companies during a career that spans over 25 years. He currently serves as Chief Technology Officer for Vir Biotechnology Inc., where he manages a multi-modality technical approach to the development of treatments for serious infectious diseases such as COVID-19, influenza and hepatitis B.